Quick answers
- What is Rifampin used for?
- The FDA-approved label (Rifampin, Mylan Institutional LLC, May 5, 2026) says: “In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Rifampin have a boxed warning?
- No. None of the 12 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Rifampin?
- The FDA drug shortage list shows “Current shortage” for a product of this medicine (updated October 23, 2026). Ask your pharmacist about alternatives.
- Has Rifampin been recalled?
- FDA enforcement reports list 9 recalls of products of this medicine; the newest started January 11, 2024 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Rifampin?
- 13 companies list prescription products of Rifampin in the FDA NDC Directory, including Epic Pharma, LLC, Chartwell RX, LLC and ANI Pharmaceuticals, Inc..
What Rifampin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. …
— FDA label: Rifampin, Mylan Institutional LLC, effective May 5, 2026. Read the full label on DailyMed →
The FDA has 12 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 12 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule · Injection, powder, lyophilized, for solution |
|---|---|
| Route | Oral · Intravenous |
| Prescription products | 19 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| rifampin 150 mg capsule | Generic | $0.9816 per capsule |
| rifampin 300 mg capsule | Generic | $0.6717 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Epic Pharma, LLC2 products
- Chartwell RX, LLC2 products
- ANI Pharmaceuticals, Inc.2 products
- Puracap Laboratories LLC dba Blu Pharmaceuticals2 products
- American Health Packaging2 products
- Lupin Pharmaceuticals, Inc.2 products
- Mylan Institutional LLC1 product
- Hikma Pharmaceuticals USA Inc.1 product
- Major Pharmaceuticals1 product
- Coupler LLC1 product
- A-S Medication Solutions1 product
- Fresenius Kabi USA, LLC1 product
- Bryant Ranch Prepack1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (7)
- ANDA064150Epic Pharma LLC · May 28, 1997
- ANDA065390Chartwell Molecular · March 28, 2008
- ANDA065421Mylan Labs Ltd · May 22, 2008
- ANDA090034Lupin Pharms · August 21, 2013
- ANDA091181Fresenius Kabi USA · August 21, 2014
- ANDA205039Hikma Pharms · March 3, 2016
- ANDA219918Novitium Pharma · June 29, 2026
Shortage status
Current shortage · updated October 23, 2026 · first posted December 22, 2021
| Product | Rifampin, Capsule, 300 mg (NDC 42806-799-01) |
|---|---|
| Availability | Unavailable |
| Reason given | Discontinuation of the manufacture of the drug |
| Company | Epic Pharma, LLC |
Ask your pharmacist whether your product is affected and what the options are.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 11, 2024 · Class II · Terminated · D-0285-2024
Failed Impurities/Degradation Specification.
Rifampin Capsules USP, 150 mg, 30 Capsules (3 x 10) unit doses per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 60687-575-21; NDC Unit Dose: 60687-575-11 — Amerisource Health Services LLC
-
January 5, 2024 · Class II · Terminated · D-0283-2024
Subpotent Drug and Failed Impurities/Degradation Specifications
Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-658-06 — Lupin Pharmaceuticals Inc.
-
January 5, 2024 · Class II · Terminated · D-0284-2024
Subpotent Drug and Failed Impurities/Degradation Specifications
Rifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-659-06 — Lupin Pharmaceuticals Inc.
-
December 20, 2022 · Class II · Terminated · D-0165-2023
Failed Impurities/Degradations Specifications
Rifampin Capsules USP, 300 mg, 100 Capsules (10 x 10) per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC 60687-586-01 (Individual Dose NDC: 60687-586-11) — Amerisource Health Services LLC
-
December 12, 2022 · Class II · Terminated · D-0100-2023
Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.
Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06 — Lupin Pharmaceuticals Inc.
-
July 28, 2022 · Class II · Terminated · D-1343-2022
CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.
Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06 — Lupin Pharmaceuticals Inc.
-
April 7, 2022 · Class II · Terminated · D-0774-2022
Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.
Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60 — Mylan Pharmaceuticals Inc
-
October 7, 2019 · Class II · Terminated · D-0139-2020
Failed Impurities/Degradation Specifications: discoloration due to elevated unknown impurity results which could decrease the effectiveness of the product.
Rifampin for Injection, USP, 600 mg/vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103; NDC 67457-445-60. — Mylan Laboratories Limited (Sterile Products Division)
-
June 4, 2015 · Class II · Terminated · D-1234-2015
Failed Impurities/Degradation Specifications; out-of-specification for color, impurity, and degradation
Rifampin for Injection, USP 600mg/vial in a 20mL vial, Rx only, Manufactured for Fresenius Kabi LLC 3 Corporate Drive, Lake Zurich, IL, 60047, by Fresenius Kabi LLC, 2020 N Ruby Street, Melrose Park, IL 60160. NDC 63323- — Fresenius Kabi USA, LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 198201, 198202, 312821 |
|---|---|
| SPL set ID of the quoted label | 8be91604-d7cd-4f2b-997d-e3364e4092e5 |
| FDA labels (SPL) | 12 |
| FDA applications | 7 ANDA |
| Active ingredients (FDA) | RIFAMPIN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Rifampin, Mylan Institutional LLC, effective May 5, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →